Reck, Folkert, Bermingham, Alun, Blais, Johanne, Cazarez, Anthony, Colvin, Richard, Dean, Charles, Furegati, Markus, gamboa, Luis, Growcott, Ellena, Li, Cindy, Lopez, Sara, Metzger, Louis, Nocito, Sandro, Ossola, Flavio, Rasper, Dita, Yue, Qin, Phizackerley, Kaci, Shaul, Jacob, Shen, Xiaoyu, Simmons, Robert L, Tang, Dazhi and Tashiro, Kyuto (2019) IID572: A New Potentially Best-In-Class β-Lactamase Inhibitor. ACS infectious diseases. ISSN 23738227

Abstract

Resistance in Gram-negative bacteria to β-lactam drugs is mediated primarily by the expression of β-lactamases, and co-dosing of β-lactams with a β-lactamase inhibitor (BLI) is a clinically proven strategy to address resistance. New β-lactamases that are not impacted by existing BLIs are spreading and creating the need for development of novel broader spectrum BLIs. IID572 is a novel broad spectrum BLI of the diazabicyclooctane (DBO) class that is able to restore the antibacterial activity of piperacillin against piperacillin/tazobactam-resistant clinical isolates. IID572 is differentiated from other DBOs by its broad inhibition of β-lactamases and the lack of intrinsic antibacterial activity.

Item Type:	Article
Keywords:	antibiotic DBOs diazabicyclooctane piperacillin β-lactamase inhibitors
Date Deposited:	14 May 2019 00:45
Last Modified:	14 May 2019 00:45
URI:	https://oak.novartis.com/id/eprint/38466